NCT06500273Phase 2Recruiting

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Study sponsor: Allogene Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-12Estimated
Enrollment · participants250Estimated
Source updated2026-10-30Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Primary completion date changed

Before: 24 Aug 2027. After: Dec 2027.

Check registry source